Your browser doesn't support javascript.
Childhood cancer survivorship care during the COVID-19 pandemic: an international report of practice implications and provider concerns.
van den Oever, Selina R; Pluijm, Saskia M F; Skinner, Rod; Glaser, Adam; Mulder, Renée L; Armenian, Saro; Bardi, Edit; Berger, Claire; Ehrhardt, Matthew J; Gilleland Marchak, Jordan; Haeusler, Gabrielle M; Hartogh, Jaap den; Hjorth, Lars; Kepak, Tomas; Kriviene, Izolda; Langer, Thorsten; Maeda, Miho; Márquez-Vega, Catalina; Michel, Gisela; Muraca, Monica; Najib, Mohamed; Nathan, Paul C; Panasiuk, Anna; Prasad, Maya; Roganovic, Jelena; Uyttebroeck, Anne; Winther, Jeanette F; Zadravec Zaletel, Lorna; van Dalen, Elvira C; van der Pal, Helena J H; Hudson, Melissa M; Kremer, Leontien C M.
  • van den Oever SR; Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS, Utrecht, the Netherlands. s.r.vandenoever-2@prinsesmaximacentrum.nl.
  • Pluijm SMF; Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS, Utrecht, the Netherlands.
  • Skinner R; Great North Children's Hospital, and Translational and Clinical Research Institute, Newcastle University Centre for Cancer, Newcastle University, Newcastle upon Tyne, UK.
  • Glaser A; Leeds Institute of Medical Research, University of Leeds, Leeds, LS2 9JT, UK.
  • Mulder RL; Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS, Utrecht, the Netherlands.
  • Armenian S; City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
  • Bardi E; St Anna Childrens Hospital, Vienna, Austria.
  • Berger C; Department of Pediatrics and Adolescent Medicine, Kepler University Clinic, Linz, Austria.
  • Ehrhardt MJ; Department for Pediatric Hematology and Oncology CHU Nord, University Hospital Saint-Etienne, Saint-Priest en Jarez, France.
  • Gilleland Marchak J; U1059 Sainbiose, University Jean Monnet, Saint-Etienne, France.
  • Haeusler GM; Department of Oncology, St. Jude Children's Research Hospital, Memphis, TN, USA.
  • Hartogh JD; Department of Epidemiology and Cancer Control, St. Jude Children's Research Hospital, Memphis, TN, USA.
  • Hjorth L; Department of Pediatrics at, Emory University School of Medicine, Aflac Cancer & Blood Disorders Center at Children's Healthcare of Atlanta, Atlanta, GA, USA.
  • Kepak T; Paediatric Integrated Cancer Centre, Victoria, Australia.
  • Kriviene I; Murdoch Childrens Research Institute, Melbourne, VIC, Australia.
  • Langer T; Royal Childrens Hospital, Melbourne, VIC, Australia.
  • Maeda M; Dutch Childhood Cancer Parent Organization VOKK Netherlands, Department VOX Survivors, Nieuwegein, The Netherlands.
  • Márquez-Vega C; Department of Paediatrics, Skåne University Hospital Clinical Sciences, Lund University, Lund, Sweden.
  • Michel G; University Hospital Brno & International Clinical Research Center (FNUSA-ICRC), Masaryk University, Brno, Czech Republic.
  • Muraca M; Republican Siauliai County Hospital, Siauliai, Lithuania.
  • Najib M; Vilnius University Siauliai Academy, Siauliai, Lithuania.
  • Nathan PC; Pediatric Hematology and Oncology, Hospital for Children and Adolescents, University Hospital of Schleswig-Holstein, Campus Luebeck, Luebeck, Germany.
  • Panasiuk A; Department of Pediatrics, Nippon Medical School, Tokyo, Japan.
  • Prasad M; Department of Pediatric Oncology, Hospital Virgen del Rocío, Sevilla, Spain.
  • Roganovic J; Department of Health Sciences and Medicine, University of Lucerne, Frohburgstrasse 3, PO Box 4466, 6002, Lucerne, Switzerland.
  • Uyttebroeck A; Epidemiology and Biostatistics Unit and DOPO Clinic, IRCCS Istituto Giannina Gaslini, Genova, Italy.
  • Winther JF; Hospital Tunku Azizah, Kuala Lumpur, Malaysia.
  • Zadravec Zaletel L; Division of Haematology/Oncology, The Hospital for Sick Children, Toronto, Canada.
  • van Dalen EC; Department of Paediatric Bone Marrow Transplantation, Oncology and Haematology, Medical University of Wroclaw, Wroclaw, Poland.
  • van der Pal HJH; Paediatric Oncology, Tata Memorial Hospital, Mumbai, India.
  • Hudson MM; Department of Pediatrics, Clinical Hospital Centre Rijeka and School of Medicine of the University of Rijeka, Rijeka, Croatia.
  • Kremer LCM; Department of Pediatric Hematology and Oncology, University Hospitals Leuven, Leuven, Belgium.
J Cancer Surviv ; 16(6): 1390-1400, 2022 Dec.
Article in English | MEDLINE | ID: covidwho-1638669
ABSTRACT

PURPOSE:

Long-term follow-up (LTFU) care is essential to optimise health outcomes in childhood cancer survivors (CCS). We aimed to assess the impact of the COVID-19 pandemic on LTFU services and providers.

METHODS:

A COVID-19 working group within the International Late Effects of Childhood Cancer Guideline Harmonization Group (IGHG) distributed a questionnaire to LTFU service providers in 37 countries across Europe, Asia, North America, Central/South America, and Australia. The questionnaire assessed how care delivery methods changed during the pandemic and respondents' level of worry about the pandemic's impact on LTFU care delivery, their finances, their health, and that of their family and friends.

RESULTS:

Among 226 institutions, providers from 178 (79%) responded. Shortly after the initial outbreak, 42% of LTFU clinics closed. Restrictions during the pandemic resulted in fewer in-person consultations and an increased use of telemedicine, telephone, and email consultations. The use of a risk assessment to prioritise the method of LTFU consultation for individual CCS increased from 12 to 47%. While respondents anticipated in-person consultations to remain the primary method for LTFU service delivery, they expected significantly increased use of telemedicine and telephone consultations after the pandemic. On average, respondents reported highest levels of worry about psychosocial well-being of survivors.

CONCLUSIONS:

The pandemic necessitated changes in LTFU service delivery, including greater use of virtual LTFU care and risk-stratification to identify CCS that need in-person evaluations. IMPLICATIONS FOR CANCER SURVIVORS Increased utilisation of virtual LTFU care and risk stratification is likely to persist post-pandemic.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Cancer Survivors / COVID-19 / Neoplasms Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study / Qualitative research Limits: Child / Humans Language: English Journal: J Cancer Surviv Year: 2022 Document Type: Article Affiliation country: S11764-021-01120-9

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Cancer Survivors / COVID-19 / Neoplasms Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study / Qualitative research Limits: Child / Humans Language: English Journal: J Cancer Surviv Year: 2022 Document Type: Article Affiliation country: S11764-021-01120-9